At the news
? NEUTRALIMPACT 3/10 8-K filed Jun 2, 2026 at 16:01 ET
Forte Biosciences filed an 8-K reporting the results of its 2026 annual meeting, where stockholders approved the amended and restated 2021 Equity Incentive Plan (adding 1,850,000 new shares for a total reserve of 5,190,000 shares) and re-elected three Class III directors. The filing is a routine governance update with no material financial data or operational changes.
- Stockholders approved the Amended and Restated 2021 Equity Incentive Plan with 11,911,879 votes for, 3,997,050 against, and 351,042 abstentions.
- The plan reserves 5,190,000 shares total, including 1,850,000 newly requested shares.
- Three Class III directors (Steven Kornfeld, Scott Brun, Paul A. Wagner) were re-elected.
- KPMG LLP was ratified as independent auditor for FY2026 with 17,722,893 votes for.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access